Business

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

The Economic Times · 24 August 2026 at 6:20 am

Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations.

The company holds a global leadership position in corticosteroid and steroidal-hormone APIs.

Its revenue primarily comes from international markets, with Europe being a significant contributor.

Financials show steady revenue and EBITDA growth over recent years.

Investors with a high-risk appetite may consider this long-term opportunity.

Read the full article on The Economic Times ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on economictimes.indiatimes.com — the content belongs to The Economic Times.

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

More from The Economic Times

'It's a Carry World': EM trade notches longest run since 2008

Derivatives get gen Z twist, but losses cast a long shadow: Sebi

Global Market Today: Asian stocks dip with AI in focus, oil declines

IPO rush continues: 10 issues to raise over Rs 3,500 crore this week

More in Business

Vessels violating Hormuz protocols shall face fines, detention: Iran

Not a single drop of oil will be exported if US economic war persists: Iran

Entering endgame: US Treasury secy announces economic D-Day against Iran

Personal loan prepayment: Should you close early? Experts explain financial impact and potential savings

'It's a Carry World': EM trade notches longest run since 2008

Derivatives get gen Z twist, but losses cast a long shadow: Sebi